Just Block This Right Here, Thanks

Dec 05, 2009

A hepatitis C drug from Santaris targeting a microRNA is now in the early stages of clinical testing, reports Technology Review. The drug, a synthetic nucleic acid, binds miR-122, which the hepatitis C virus needs to reproduce.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Main menu